Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Ltd

Godavari Biorefineries Ltd , through its clinical-stage biotech division Sathgen Therapeutics, has been granted a patent by China’s patent and trademark office for its novel anti-cancer molecule, the company said.

The patent covers a novel class of compounds “that have exhibited strong inhibitory effects on cancer and cancer stem cells in vitro studies,” it said. These compounds have demonstrated significant efficacy against multiple cancer cell types, including breast and prostate cancer, it added.

“Our focus on original, high-quality science continues to guide our journey beyond green chemistry into life sciences,” said Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Ltd .

Godavari Biorefineries has a global presence, exporting to over 20 countries with links to international research and development networks. The company’s clinical-stage biotech division, Sathgen Therapeutics, is at the forefront of advancing novel cancer and antiviral therapies. With a lead molecule undergoing clinical trials and global patent protection, GBL is intensifying itsfocus in translational research to addresses some of the world’s most urgent health challenges, a note from the company said.

Published on July 22, 2025



Source link